Business · 02/10/2020
FDA Announces Draft Guidance for Developing Drugs and Biologics for Renal Cell Carcinoma Adjuvant Treatment
The FDA has released a draft guidance document outlining recommendations for the development of drugs and biologics for the adjuvant treatment of renal cell carcinoma, aiming to facilitate the creation of new treatments for this cancer type.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →